Zijian Zhao

1. Led the development of Roche’s Obesity Disease Area Strategy and 10-year ambitions 2. Led global early commercial team for Roche’s next generation Obesity injectable portfolio and assets. 3. Led Roche-Zealand Pharma Joint Commercial Team under strategic alliance agreement. 4. Led commercial path-to-value assessment for both internal R&D and external BD&L assets, advancing internal asset development and external assets DD / acquisitions to further strengthen Roche’s portfolio continuity and sustained growth. 5. Led integrated development and commercial planning (IDCP) feeding into robust asset lifecycle strategies aligning TPP, CDP, Access, Forecasting, Go-to-Market, Device and delivery. 6. Received Roche Impact Award 2025 for Roche’s external strategic partnership with Zealand Pharma.

1. Led the development of Roche Group China Strategy by identifying opportunities and building strategic plans across the full pharma value chain incl. R&D, Manufacturing, Commercial, BD&L (both C4G and C4C models) to maximize impact of Roche’s medicines on Chinese patients and deliver Roche’s long term ambition in China and beyond. 2. Led the realization of the Group China Strategy by facilitating global sr. leadership alignment and key CapEX and OpEx investment decisions, orchestrating end to end execution of Roche China strategy across the full value chain at both global and local levels. 3. Received Roche Impact Award 2024 for Roche Group China Strategy implementation.

1. Responsible for Oncology medical portfolio strategy, project prioritization and investment guidance across Global, Region and Countries (> 500 mUSD budget / year). 2. Developed and led Oncology Life Cycle Management framework jointly with Research, Development, BD&L, Medical Affairs, Marketing, Access, Supply Chain and the Affiliates to maximize value of assets throughout the life-cycle. 3. Led Oncology launch excellence framework and regular oncology leadership launch readiness reviews. Provide coaching and support to countries to ensure launch readiness and pull-through. 4. Led Oncology cross-functional disease area strategy planning and review process for both solid tumors (Lung, Breast, Prostate and GI) and hematology (malignant and benign) franchises. 5. Developed and led integrated evidence framework to bridge efforts across Development, Medical Affairs, Marketing, Access and Affiliates to enable tailored and fit-for market evidence ideation, generation and dissemination to effectively remove registration barriers, expand access, drive adoption and fight competition. 6. Developed and lead integrated insights framework and ecosystem advocacy tracking solutions via partnering with consultancy firms (McKinsey, Veeva, IQVIA etc.) and industry forums to bring-in industry insights, benchmarks, best practices, key market trends, and competitive intelligence to enable better informed decisions. 7. Received CEO Award for Oncology Launch Excellence and CMO Award for end-to-end LCM framework.

With nearly the same span of responsibilities as above, promoted to establish and lead global portfolio strategy team after 6 months in role.

1. Member of IO-CMR leadership team, heading up CMR strategy and project management, served as right-hand person to IO-CMR SVP in all corporate agendas. 2. Led the development of IO-CMR strategy and provided guidance to functional teams and affiliates. Oversee and manage cross-functional strategic projects engaging with Clinical Development, Medical Affairs, Regulatory, Marketing, Market Access and Regions/Countries. 3. R&D finance partner to IO-CMR SVP managing all CMR related financial issues and oversee budget accuracy and compliance. Lead CMR strategic planning process incl. financial budgeting during AB/RE, Organization Reviews, resource planning and expansion across the geography (600 to 2000+ CMR FTEs) 4. Provide business support to the leadership Team. Gathering insights, building business cases and recommendations to enable informed management decisions. 5. Led CMR performance management process incl. target setting, cascading and reporting across IO (more than 2,000 CMR employees in a matrix organization across global, regions and countries). 6. Led CMR operational excellence framework incl. development of methodology, performance metrics, benchmarking, diagnosis tools and improvement recommendations. Executed CMR operational excellence projects incl. clinical trial productivity improvement, medical organizational excellence and cross-functional process improvement projects. 7. Supported IO-CMR SVP in organizational transformation of Clinical Operations, Medical Affairs and Regulatory Affairs from task-oriented operational functions into strategic functions with high impact on business and enhanced cross-functional collaboration, as well as setup of regional CDC hubs across IO.

Based in China, Denmark and Zurich with growing responsibilities within CMR organization, played a pivotal role in managing R&D resource expansion within IO (from 100 to 600+ FTEs) and the integration of clinical development, medical affairs, regulatory, quality and PV functions to establish the new CMR organizations at IO, regional, BA and affiliate level.

Leadership, Corporate Strategy, Finance, Operations, Supply Chain Management, Organizational Transformation, Entrepreneurship (incl. start-up pitch in Silicon Valley), Digital Transformation. Completed Business expeditions in Kenya (Nairobi), USA (Silicon Valley) and China (Shenzhen). Written business case accepted and published by IMD business school

Tumor Immunology, Checkpoint Blockade, CAR-T, BiTE, Tumor Vaccines, Oncolytic Virus and other Novel Therapies including Clinical applications, Cancer Genomics, Tumor Sequencing, Diagnosis and Precision Medicine

R&D project valuation (forecasting, eNPV, eROCE, probability of success, Monte Carlo simulation), product lifecycle management, Pharma/Biotech Venture Capital, due diligence, BD&L / M&A